Open AccessThe Comparison of Melphalan Administration on Day −3 With Administration on Day −1 on Neutrophil and Platelet Engraftment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Author(s) -
Ali Ünal,
Leylagül Kaynar,
Nermin Keni,
Bülent Eser,
Mustafa Çetın,
Esra Yıldızhan,
Fatma İlknur Varol,
Sefa Çiftçi
Publication year - 2018
Publication title -
journal of global oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.002
H-Index - 17
ISSN - 2378-9506
DOI - 10.1200/jgo.18.88300
Subject(s) - melphalan , medicine , multiple myeloma , regimen , chemotherapy , absolute neutrophil count , surgery , platelet , neutropenia
Background: High dose chemotherapy followed by ASCT is the most important step of MM treatment. Melphalan, an alkylating agent, is the most preferable drug for conditioning regimens and dosage and timing is important with regard to side effects or engraftment timing. Engraftment time is determinative on infections and hospitalization duration. Aim: To compare of the neutrophil and thrombocyte engraftment time in patients with multiple myeloma who received melphalan 200 mg/m 2 single dose on day −3 and day −1 as conditioning regimen. Methods: We compared the neutrophil and thrombocyte engraftments retrospectively in patients with multiple myeloma who received melphalan 200 mg/m 2 single dose on day −3 and day −1 as conditioning regimen. There were 29 patient receiving melphalan on day −1 and 42 patient on day −3. Results: Administration of melphalan on day −3 was better than on day. Neutrophil engraftment time and hospitalization duration was shorter in patients who received melphalan on day −3 than patients who received melphalan on day −1. In day −3 group, there was no failure neither in neutrophil nor in thrombocyte engraftment but 1 patient could just get thrombocyte engraftment on day 33. In day −1 group, 2 patients could not get engraftment. Conclusion: Administration of melphalan on day −3 is better than on day −1 in terms of neutrophil engraftment and hence in terms of hospitalization duration.